GE HealthCare CFO Transition & Capital Allocation Studio

Capital Levers & Scenarios

Revenue Growth Target: 4.5%

Operating Margin Target: 15.8%

R&D Reinvestment Intensity: 5.5%

Bolt-on M&A Budget ($B): $1.2B

Share Repurchases ($B): $0.8B

Debt Reduction Target ($B): $1.0B

Imaging (52%)

Rev: $10.6B | R&D: $584M

Ultrasound (18%)

Rev: $3.7B | R&D: $202M

Patient Care (16%)

Rev: $3.3B | R&D: $180M

Pharma Diag (14%)

Rev: $2.9B | R&D: $157M

Net Leverage Ratio

2.01x

Safe (< 2.50x covenant)

Free Cash Flow (FCF)

$2.68B

Conversion: 85%

3-Yr Projected EPS

$4.82

+8.2% CAGR

Capital Headroom

+$0.68B

Surplus Capacity